Patents Assigned to Merck
  • Electro-optical liquid-crystal display
    Patent number: 6602562
    Abstract: The invention generally relates to an electro-optical liquid-crystal display having a re-alignment layer, for re-aligning the liquid crystals, whose field has a component parallel to the liquid-crystal layer which is desirable for the re-alignment, including a liquid-crystalline medium of positive dielectric anisotropy, where the medium can include one or more compounds of the formula I and one or more compounds selected from the group of compounds of the formulae II and III in which R1, R2 and R3 are each, independent of one another, alkyl or alkoxy having 1 to 7 carbon atoms or alkenyl, alkenyloxy or alkoxyalkyl having 2 to 7 carbon atoms, Y11, Y12, Y21, Y22, Y31 and Y32 are each, independent of one another, H or F, are each, independent of one another,  and Q—X is F, Cl, —OCF2H or —OCF3.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Shinji Nakajima, Hideo Ichinose, Akiko Takashima, Yasushi Sugiyama
  • Polyesters containing (meth)acrylate end groups
    Patent number: 6602963
    Abstract: The invention describes polyesters containing (meth)acrylate end groups, of the general formula (I) CH2═CRCOO—PE—OCOCR═CH2 where R=CH3 or H, where PE=[—A—OCO—B—COO—]m—A—, [—CHR′—COO—]n—A—[—OCOCHR′—]n, or combinations thereof, in which A is an alkylidene radical having 2-20 carbon atoms or an alkoxylidene radical having 2-1000, preferably 2-500, alkoxylidene units, B is a saturated alkylidene radical having 2-10 carbon atoms, R′ is H or CH3, m is 1-100, n is 1-100, and, if both m and n are present, the sum m+n is 2-200, where the polyesters containing (meth)acrylate end groups are characterized in that a) the content of short-chain di(meth)acrylates (II) CH2═CRCOO—A—OCOCR═CH2 is <5% by weight, b) the content of hydroxyl groups is <0.25 mol/mol of (meth)acrylate, and c) the APHA color number is <200.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Werner Siol, Peter Pokinskyj
  • Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids
    Patent number: 6603013
    Abstract: The present invention relates to a process wherein heterogeneous finely-dispersed palladium catalysts are used in a cross-coupling reaction of alkenyl halides and aryl or heteroaryl boronic acids in the presence of base in an aprotic solvent to produce aryl- or heteroaryl-olefin compounds of Formula I:
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Yongkui Sun, Carl LeBlond, John R. Sowa, Jr.
  • Use of ectoine or ectoine derivatives in cosmetic formulations
    Patent number: 6602514
    Abstract: The use of one or more compounds chosen from the compounds of the formulae Ia and Ib the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R1, R2, R3, R4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Bünger, Hans-Jürgen Driller, Roland Martin
  • Substituted pyridazines having cytokine inhibitory activity
    Patent number: 6602872
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Charles J. McIntyre, Nigel J. Liverton, David A. Claremon
  • Apparatus and method for processing phone-in prescriptions
    Publication number: 20030144876
    Abstract: An apparatus and method are disclosed for processing phone-in prescription requests. The apparatus is in the form of a prescription processing network that includes a prescription processing system and a communication device remotely located from the prescription processing system. The communication device is used to establish a communication channel with the prescription processing system and submit a prescription request over the communication channel. A pharmacist, associated with the prescription processing system, prepares a completed prescription form based, at least in part, on the submitted prescription request. The prescription processing network also includes a pharmacy for receiving the completed prescription form, and filling the prescription request based on the completed prescription form.
    Type: Application
    Filed: January 28, 2002
    Publication date: July 31, 2003
    Applicant: Merck-Medco Managed Care, LLC
    Inventors: Diana L. Kosinski, Mark W. Sullivan, Steven M. McNamara, Melissa Russo
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
    Publication number: 20030144327
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: July 31, 2003
    Applicant: Merck & Co., Inc.
    Inventor: Louis S. Crocker
  • Growth hormone secretagogue related receptors and nucleic acids
    Patent number: 6599718
    Abstract: This invention relates to a new family of receptors, growth hormone secretagogue-related receptors, which exhibit moderate sequence identity to both the growth hormone secretagogue receptor (GHS-R) and the neurotensin receptor (NT-R). These newly identified receptors are expressed in a diverse set of tissues. This invention also relates to nucleic acids encoding these receptors, and to the use of these receptors to identify ligands that modulate growth hormone release as well as other modulators of endocrine function.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Qingyun Liu, Andrew D. Howard, Karen Kulju McKee
  • Process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1, 4-oxazine
    Patent number: 6600040
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Karel M. Jos Brands, Fuh-Rong Tsay, Karen M. Conrad, Matthew M. Zhao
  • Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfony)phenyl]ethanone
    Patent number: 6600046
    Abstract: The process for preparing 1-(6-methylpyridin-3-yl)-2-[(4-methlsulfonyl)-phenyl]ethanone of the formula I: In a first step, 4-(methylthio)phenylacetonitrile is condensed with a 6-methylnicotinic ester to give 3-[2-(4-(methlthio)phenyl)-2-cyanoacetyl](6-methyl)pyridine of the formula II: In a second step, the compound of formula II is hydrolyzed and decarboxylated under acidic conditions using a mixture of acetic acid and a mineral acid, to give 3-[2-(4-(methylthio)phenyl)acetyl](6-methyl)pyridine of the formula III: Finally, in a last step, the compound of formula III is oxidized to give the end product.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: July 29, 2003
    Assignees: Merck & Co., Inc., Lonza AG
    Inventors: Yves Bessard, James Edward Leresche
  • Film
    Patent number: 6599443
    Abstract: The invention relates to an optical retardation film comprising a layer of an anisotropic polymer material with an optical axis substantially parallel to the plane of the layer. The invention furthermore relates to a process of preparing the optical retardation film, to the use of such an optical retardation film in liquid crystal displays, and to a liquid crystal display device comprising a liquid crystal cell and such an optical retardation film.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: July 29, 2003
    Assignees: Rockwell Technologies, LLC, Merck Patent GmbH
    Inventors: Nicholas Sharples, Gabrielle Egan, Young Chung, Zhiming Zhuang, Zili Li, Bruce K. Winker, Jane H. Hanamoto, David Coates
  • Method of establishing synthesis paths
    Patent number: 6600970
    Abstract: A method of establishing a synthesis path in a multiplicity of potentially interlinakable reactions, and a computer program to prepare a synthesis path.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck Patent GmbH
    Inventor: Klemens Bley
  • Interference pigments with great color strength
    Patent number: 6599355
    Abstract: The invention relates to interference pigments with a great color strength that are based on multicoated platelet-shaped substrates that have at least one series of layers from (A) a highly refractive coating that consists of a mixture of TiO2 and Fe2O3 in ratio of 1:0.1 to 1:5 and optionally one or more metal oxides in amounts of ≦20% by weight based on layer (A), (B) a colorless coating with a refractive index n≦1.8, (C) a colorless coating with a refractive index of n 1.8, (D) an absorptive coating with a refractive index of n 1.8, and optionally (E) an outer protective layer.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: July 29, 2003
    Assignee: Merck Patent GmbH
    Inventors: Christoph Schmidt, Klaus Bernhardt, Sabine Schoen, Dieter Heinz
  • Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
    Publication number: 20030138911
    Abstract: Nucleic acid molecules encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing the nucleic acid molecules, and methods for producing alpha and beta subunits are provided. In particular, nucleic acid molecules encoding &agr;6 subunits and molecules encoding &bgr;3 subunits of human neuronal nicotinic acetylcholine receptors are provided. In addition, combinations of a plurality of subunits, such as one or more of &agr;1, &agr;2, &agr;3, &agr;4, &agr;5, &agr;6 and/or &agr;7 subunits in combination with one or more of &bgr;3 subunits or such as one or more of &bgr;2, &bgr;3 and/or &bgr;4 subunits in combination with an &agr;6 subunit are provided.
    Type: Application
    Filed: January 23, 2003
    Publication date: July 24, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Kathryn J. Elliott, Michael M. Harpold
  • Nematic liquid-crystal composition
    Publication number: 20030136945
    Abstract: The invention relates to nematic liquid-crystal compositions comprising bisalkenyl compounds of the formula I 1
    Type: Application
    Filed: October 15, 2002
    Publication date: July 24, 2003
    Applicant: Merck Paten GmbH
    Inventors: Harald Hirschmann, Sven Schupfer, Marcus Reuter
  • Liquid-crystalline medium
    Patent number: 6596350
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R, A1, Z1, Y and L are as defined herein.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka
  • Aluminum alkyl complexes as cocatalysts
    Patent number: 6596890
    Abstract: Organometallic aluminum compounds of the general formula (I) where X1 is NH, NH2*, NH—A*, N—A, N(A)2*, O, OA*, O-Aryl*, S, SA*, P, P(A)2* or a single bond, X2 is NH, N—A, O, S, PA or X1 coordinated to Al(R1)3, or a single bond, R1 is H; Hal if n=0; A which may be covalently bound to Al; Si(A)3 if X1=O, R2 is A or divalent aryl groups defined note particularly below or divalent unsaturated aliphatic groups defined more particularly below, R3 and R4 are, independently of one another, a bond or R2 or Si(A)3 or Si(A)2, Z1 is a bond or H bound to R2, Z2 is a bond or H bound to R2 or R3, A is branched or unbranched C1-C7-alkyl, C1-C7-alkylidene or C1-C7-alkenylidene, Aryl is phenyl, naphthyl, Hal is F, Cl, and, independently of one another, n, m, p and l are 0 or 1 and q is 1 or 2, where &Sgr;l+m+n≧3.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Eike Poetsch, Ludwig Pohl, Karin Weiss, Eva Maria Auth, Thomas Metzner, Herbert Schumann, Corinna Wassermann, Michael Frick, Bernd Heymer, Stefan Schutte, Ulf Dümichen, Elmar Hecht
  • Interference pigments
    Patent number: 6596070
    Abstract: The present invention relates to interference pigments on the basis of multiply coated, platelet-shaped substrates which comprise at least one layer sequence comprising (A) a coating having a refractive index n≧2.0, (B) a colorless coating having a refractive index n≦1.8, and (C) a nonabsorbing coating of high refractive index, and, if desired, (D) an external protective layer.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Christoph Schmidt, Gerhard Pfaff, Christina Schank, Sabine Schoen
  • Electrooptical liquid crystal system
    Patent number: 6596193
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electrooptical system. The electrooptical system comprises a PDLC film comprising a liquid crystal mixture forming micro- droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers. The reactive liquid crystalline compounds are of formula II, R′—G′—R″, wherein R′, G′ and R″ are as defined herein. The liquid crystal mixture comprises one or more compounds of the formula I wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process
    Patent number: 6596758
    Abstract: The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R1, R2 and (R)p have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: Michel Brunet, Jean-Jaques Zeiller, Jean-Jaques Berthelon, Francis Contard, Guy Augert, Daniel Guerrier